Pre-made Domvanalimab benchmark antibody ( Whole mAb, anti-TIGIT therapeutic antibody, Anti-VSIG9/VSTM3/WUCAM Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-152

Pre-Made Domvanalimab biosimilar, Whole mAb, Anti-TIGIT Antibody: Anti-VSIG9/VSTM3/WUCAM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-152-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Domvanalimab biosimilar, Whole mAb, Anti-TIGIT Antibody: Anti-VSIG9/VSTM3/WUCAM therapeutic antibody
INN Name Domvanalimab
TargetTIGIT
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesArcus Biosciences
Conditions Approvedna
Conditions ActiveSolid tumours;Non-small cell lung cancer
Conditions Discontinuedna
Development Techna